Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection

被引:28
作者
Mantripragada, KK [1 ]
Buckley, PG [1 ]
Jarbo, C [1 ]
Menzel, U [1 ]
Dumanski, JP [1 ]
机构
[1] Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2003年 / 81卷 / 07期
关键词
array-CGH; comparative genomic hybridization deletion/amplification detection methodology genomic microarray analysis; neurofibromatosis type 2; NF2 tumor suppressor gene;
D O I
10.1007/s00109-003-0458-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Neurofibromatosis type 2 (NF2) is an autosomal dominant cancer syndrome caused by the biallelic inactivation of the neurofibromin 2 tumor suppressor gene (NF2). Current molecular diagnostic methods for NF2 involve the detection of point mutations and/or microdeletions across the 100-kb locus from 22q12. Despite the fact that NF2 gene inactivating deletions occur in 25-30% of NF2 patients, the available approaches for high-resolution and high-throughput detection of deletions are underdeveloped. This need for improved methodology for gene copy number analysis is especially apparent when compared to a variety of methods available for accurate detection of point mutations. The microarray-based form of comparative genomic hybridization has been previously applied in the high-resolution analysis of gene copy number variation across large genomic regions. In this study we apply a PCR-based, strictly sequence-defined, repeat-free approach for the preparation of a diagnostic microarray for the detection of disease-causing deletions in the NF2 gene. The methodology is based on the preselection of target DNA by excluding redundant sequence within the NF2 locus using bioinformatics. This approach allows a significant increase in the resolution of deletion detection. The current average resolution of analysis across the NF2 locus is 23 kb. Therefore this NF2 gene-specific microarray is the first high-resolution tool for detection of diagnostically significant gene copy number aberrations. This microarray should now be applied in the analysis of an extensive series of NF2 patients, and hence we would like to call for such samples.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 27 条
[1]   Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene [J].
Albertson, DG ;
Ylstra, B ;
Segraves, R ;
Collins, C ;
Dairkee, SH ;
Kowbel, D ;
Kuo, WL ;
Gray, JW ;
Pinkel, D .
NATURE GENETICS, 2000, 25 (02) :144-146
[2]   The detection of large deletions or duplications in genomic DNA [J].
Armour, JAL ;
Barton, DE ;
Cockburn, DJ ;
Taylor, GR .
HUMAN MUTATION, 2002, 20 (05) :325-337
[3]  
Baser M. E., 2002, Neurology, V59, P1759
[4]   High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH [J].
Bruder, CEG ;
Hirvelä, C ;
Tapia-Paez, I ;
Fransson, I ;
Segraves, R ;
Hamilton, G ;
Zhang, XX ;
Evans, DG ;
Wallace, AJ ;
Baser, ME ;
Zucman-Rossi, J ;
Hergersberg, M ;
Boltshauser, E ;
Papi, L ;
Rouleau, GA ;
Poptodorov, G ;
Jordanova, A ;
Rask-Andersen, H ;
Kluwe, L ;
Mautner, V ;
Sainio, M ;
Hung, G ;
Mathiesen, T ;
Möller, C ;
Pulst, SM ;
Harder, H ;
Heiberg, A ;
Honda, M ;
Miimura, M ;
Sahlén, S ;
Blennow, E ;
Albertson, DG ;
Pinkel, D ;
Dumanski, JP .
HUMAN MOLECULAR GENETICS, 2001, 10 (03) :271-282
[5]  
Bruder CEG, 1999, GENE CHROMOSOME CANC, V25, P184, DOI 10.1002/(SICI)1098-2264(199906)25:2<184::AID-GCC15>3.0.CO
[6]  
2-B
[7]   A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications [J].
Buckley, PG ;
Mantripragada, KK ;
Benetkiewicz, M ;
Tapia-Páez, I ;
de Ståhl, TD ;
Rosenquist, M ;
Ali, H ;
Jarbo, C ;
de Bustos, C ;
Hirvelä, C ;
Wilén, BS ;
Fransson, I ;
Thyr, C ;
Johnsson, BI ;
Bruder, CEG ;
Menzel, U ;
Hergersberg, M ;
Mandahl, N ;
Blennow, E ;
Wedell, A ;
Beare, DM ;
Collins, JE ;
Dunham, I ;
Albertson, D ;
Pinkel, D ;
Bastian, BC ;
Faruqi, AF ;
Lasken, RS ;
Ichimura, K ;
Collins, VP ;
Dumanski, JP .
HUMAN MOLECULAR GENETICS, 2002, 11 (25) :3221-3229
[8]   The DNA sequence of human chromosome 22 [J].
Dunham, I ;
Shimizu, N ;
Roe, BA ;
Chissoe, S ;
Dunham, I ;
Hunt, AR ;
Collins, JE ;
Bruskiewich, R ;
Beare, DM ;
Clamp, M ;
Smink, LJ ;
Ainscough, R ;
Almeida, JP ;
Babbage, A ;
Bagguley, C ;
Balley, J ;
Barlow, K ;
Bates, KN ;
Beasley, O ;
Bird, CP ;
Blakey, S ;
Bridgeman, AM ;
Buck, D ;
Burgess, J ;
Burrill, WD ;
Burton, J ;
Carder, C ;
Carter, NP ;
Chen, Y ;
Clark, G ;
Clegg, SM ;
Cobley, V ;
Cole, CG ;
Collier, RE ;
Connor, RE ;
Conroy, D ;
Corby, N ;
Coville, GJ ;
Cox, AV ;
Davis, J ;
Dawson, E ;
Dhami, PD ;
Dockree, C ;
Dodsworth, SJ ;
Durbin, RM ;
Ellington, A ;
Evans, KL ;
Fey, JM ;
Fleming, K ;
French, L .
NATURE, 1999, 402 (6761) :489-495
[9]   A GENETIC-STUDY OF TYPE-2 NEUROFIBROMATOSIS IN THE UNITED-KINGDOM .1. PREVALENCE, MUTATION-RATE, FITNESS, AND CONFIRMATION OF MATERNAL TRANSMISSION EFFECT ON SEVERITY [J].
EVANS, DGR ;
HUSON, SM ;
DONNAI, D ;
NEARY, W ;
BLAIR, V ;
TEARE, D ;
NEWTON, V ;
STRACHAN, T ;
RAMSDEN, R ;
HARRIS, R .
JOURNAL OF MEDICAL GENETICS, 1992, 29 (12) :841-846
[10]   Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations [J].
Evans, DGR ;
Trueman, L ;
Wallace, A ;
Collins, S ;
Strachan, T .
JOURNAL OF MEDICAL GENETICS, 1998, 35 (06) :450-455